![Rasha Al-Lamee On ORBITA, ISCHEMIA, Coronary Revascularisation](https://assets.radcliffecardiology.com/s3fs-public/podcast/2024-03/EP_01_12.png?VersionId=KYAUKUXl4DT6SdGZ7TN.44WtKE.D1VK5)
Recorded before the American Heart Association (AHA) Scientific Sessions 2019, Ankur is joined by Rasha K Al-Lamee, Interventional Cardiologist at Imperial College Healthcare NHS Trust in London and Study Director of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Rasha talks about how she got into academia, the significance of her end-of-training PhD, and what led to the genesis of ORBITA.
Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
![18: The Year 2019 In Review With Sukh Nijjer](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Sukhjinder-Nijjer.png?VersionId=JTTB5Vv64hUNWcZfgTHUl0d_TqWqBpcD&itok=S8YyqYye)
Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
![EP 117: Transforming Cardiac Surgery Recovery: Evidence-Based Insights with Dr Gerdisch](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-08/DELV-23187_IND_Parallax_EP117_Gerdisch_Web_1920x1080.jpg?VersionId=10jQcg6sZufXOZ_V2.eXBcL2gcTGQckL&itok=QUtGQF0H)
Dr Gerdisch shares insights into his research on rigid sternal fixation and enhanced recovery protocols, which have shown promising results in postoperative pain management and patient recovery.
![EP 116: Navigating the Realities of Guideline Directed Medical Therapy with Dr Chahoud and Dr Israel](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-07/DELV-17584_ZOLL_Parallax_3_Web_1920x1080_0.jpg?VersionId=7AsAfHb6JltTsIeGvFIL8PjSD_bJZQC7&itok=dAPVGO1r)
![EP 115: Navigating Cultures and Cardiology: Dr Janarthanan Sathananthan's Global Journey](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-07/DELV-22085_IND_Parallax_EP116_Sathananthan_Web_1920x1080.jpg?VersionId=X7UeGqRVZ0MB.gLJ_K0aoLflMIJqb8X.&itok=QOEUH6cW)
![The Leap Year Gene with Shelley Wood, Bestselling Author & Editor-in-Chief of TCTmd](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-06/DELV-21301_Parallax_EP114_Wood_Web_1920x1080.jpg?VersionId=o3p3VftF1kaRvWNWKzolgCRXyALPXFHt&itok=H2D2X7SD)
![EP 113: Your Guide to Radiation Hygiene: Insights from Manufacturer and Users](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-06/DELV-21795_Parallax_EP113_Breininger_Radtke_Web_1920x1080.jpg?VersionId=3d524UUeTRRuHi6Y8NqMN5n1WUksM6HI&itok=Eh3lMH-C)
![EP 112: Just One Heart: Burnout, Positive Mindset & Leadership with Dr Fisher](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-05/DELV-21579_Parallax_EP112_Fisher_Web_1920x1080.jpg?VersionId=NH6WDl3W2YJSM8.eRkQN4vq5MY2xbfEd&itok=tVbLnj0V)
![EP 111: ACC 24 in Review With Dr Vallabhajosyula: 5 Trials That Will Change Your Practice](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-04/DELV-21011_Parallax_EP111_Vallabhajosyula_Web_1920x1080.jpg?VersionId=ZOcxXpbfxpQgrVCl9j7I92zCplTgt1mZ&itok=LmOEuJkd)
![EP 110: Cultivating Leadership, Civic Duty & the Presidential Leadership Programme with Dr Sinha](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-04/DELV-20782_IND_Parallax_Sinha_Web_1920x1080-2.png?VersionId=o5_ez0NqChSi.6qI0.I0LGPQ4LmwK.Ac&itok=jmdoA2eD)
![EP 109: Navigating Volume Status in Heart Failure Patients with Dr Andrew Darlington](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-03/DELV-17583_ZOLL_Parallax_2_Web_1920x1080.jpg?VersionId=bavAruPc_yuREgwZwQomlSmR8bzSje6U&itok=ybL6yurd)
Together, Dr Kalra and Dr Darlington delve into the significance of assessing volume status in patients with heart failure, highlighting its continued relevance in 2024, including the availability of new diagnostic tools, including the Heart Failure Management System (HFMS).
This series is supported by ZOLL and is intended for Health Care Professionals.
![EP 108: Song of Our Scars: Authorship & Medicine with Senior Advisor for FDA, Dr Warraich](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/DELV-19380_IND_Parallax_EP108_Warraich_Web_1920x1080.jpg?VersionId=HPs.636T_kpikJm7DK8VEDs5f0aphHbL&itok=Nh_OhD_E)
![High-Sensitivity Cardiac Troponin ACS](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Athena-%20Poppas_0.png?VersionId=uAw7s0xUwfjE1_1xcLbM7odh7YHQJw7K&itok=pSrlvyyg)
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-03/Parallax_01_1200x628.jpg?VersionId=8YtGXyCvpISHGUAWuUfXgEArl7M4TInv&itok=fTCIJSke)